Phase II Study of Erlotinib, an EGFR Inhibitor in Metastatic EGFR-positive 'Triple Receptor-negative' Breast Cancer
The goal of this clinical research study is to learn if Tarceva® (erlotinib hydrochloride) can help control triple receptor-negative breast cancer. The safety of this drug will also be studied.
To assess the clinical efficacy, biologic effects and safety of the EGFR inhibitor erlotinib in the treatment of patients with 'triple receptor-negative' metastatic carcinoma of the breast.
1) Time to progression (TTP)
- clinical benefit rate as defined by complete and partial response and stable disease
- overall survival (OS)
- safety profile and tolerability of erlotinib
- biologic correlative studies
|Study Design:||Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Study of Erlotinib, Small Molecule Targeting Epidermal Growth Factor Receptor (EGFR) in Treatment of Patients w/EGFR-overexpressing 'Triple Receptor-negative' Metastatic Carcinoma of Breast That Progressed on Anthracyclines and Taxanes|
- Time to Progression (TTP) [ Time Frame: Baseline to disease progression, up to 22 months with follow up. ] [ Designated as safety issue: No ]Time to progression calculated from the date of study entry to the date of disease progression or death. Progression of disease is defined by RECIST (Response Evaluation Criteria In Solid Tumors) criteria, as measurable increase in the smallest dimension of any target or not-target lesion, or the appearance of new lesions, since baseline. Confirmed response based on two tumor assessments (imaging) separated by at least 4 weeks.
|Study Start Date:||July 2008|
|Study Completion Date:||November 2010|
|Primary Completion Date:||November 2010 (Final data collection date for primary outcome measure)|
Experimental: Tarceva daily
Tarceva oral 150 mg daily.
Tarceva (erlotinib hydrochloride) given alone, at 150 mg by mouth daily.
Show Detailed Description
Please refer to this study by its ClinicalTrials.gov identifier: NCT00739063
|United States, Texas|
|UT MD Anderson Cancer Center|
|Houston, Texas, United States, 77030|
|Principal Investigator:||Bryan Hennessy, MD/Asst Prof||UT MD Anderson Cancer Center|